27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The Mediterranean diet (MedDiet), one of the most studied and well-known dietary patterns worldwide, has been associated with a wide range of benefits for health. 3 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
J-MINT demonstrates cost-effectiveness by reducing overall care costs while improving QALYs in individuals with MCI. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This case report explores the therapeutic potential of lymphovenous bypass (LVB) surgery performed at the neck in neurodegenerative diseases, specifically Alzheimer's disease (AD) dementia. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) and sarcopenia are prevalent age-related conditions that often coexist and share common mechanisms such as chronic inflammation, reduced neuroplasticity, and impaired muscle function. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Depression in Alzheimer's disease (AD) dementia has become an increasingly recognized public health concern due to its high prevalence and substantial impact on patient outcomes. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
During a median follow-up period of 4.6 years, stroke, MACEs, and AD dementia occurred in 24, 36, and 21 patients, respectively. 5 key findings →
Design: post-hoc analysis Participants: 1,011 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The history of medical and psychiatric use of lithium dates back to more than one and a half-century ago. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Frailty syndrome encompasses several physical hallmarks such as loss of muscle strength, power output and mass, which leads to poor gait ability, fatigue, falls and overall difficulty to perform activities of daily living. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
In addition to the well-documented relationship between peripheral hearing loss and cognition highlighted in previous comprehensive reviews, there is also some evidence to suggest that there is a relationship between central hearing impairment and cognition. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Although cognitive and functional impairment are the hallmark features of Alzheimer's disease (AD), neuropsychiatric symptoms associated with AD account for increased rates of disability and profoundly impact the quality of life of both patients and their caregivers. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
ANCOVA (age and schooling as covariates) displayed statistically significant results with respect to CSF biomarkers' profiles regardless of the socio-demographic divergencies previously identified by one-way ANOVA. 5 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source
As the United States population ages, a higher share of adults is likely to use long-term services and supports. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease (AD) primarily affects older adults. 5 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundScreening for cognitive function, using tests such as the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), is the first step in detecting mild cognitive impairment (MCI) and dementia. 2 key findings →
Design: post-hoc analysis Participants: 940 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Early diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The MIND diet may buffer the cognitive consequences of cerebrovascular pathology and cortical atrophy in older adults at elevated dementia risk and promote cognitive resilience over general healthy eating guidelines. 2 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The primary analysis demonstrated significant improvements in multiple episodic memory measures across both intervention groups, with no significant differences observed between groups. 5 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This narrative review examines literature pertaining to possible physiological explanations for observed cognitive benefits stemming from improvements to cardiovascular fitness following chronic aerobic exercise. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Postoperative cognitive dysfunction (POCD) is an objectively measured decline in cognition postoperatively compared with preoperative function. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Older people with cognitive impairment are at increased risk of falls; however, fall prevention strategies have limited success in this population. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Overall, the application of ML to mental health has demonstrated a range of benefits across the areas of diagnosis, treatment and support, research, and clinical administration. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Case management for persons with dementia may increase use of community-based services and delay nursing home admission. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
RODBELLFREDRICKSON MDS: The nature of the proteins associated with dog and human chylomicrons. 1 key finding →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundLecanemab is the first approved disease-modified therapy in Japan for patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (AD-D).ObjectiveThis study aims to evaluate the social value of lecanemab in Japan. 1 key finding →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Frontotemporal dementia (FTD) is a dementia syndrome characterized by peculiar behavioral changes arising from frontotemporal involvement and distinct from Alzheimer's disease (AD). 4 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →